



(12) Translation of
European patent specification

(11) NO/EP 3398961 B1

NORWAY

(19) NO
(51) Int Cl.
C07K 14/605 (2006.01)
A61K 38/26 (2006.01)

Norwegian Industrial Property Office

| | | |
|------|--|---|
| (45) | Translation Published | 2022.10.10 |
| (80) | Date of The European Patent Office Publication of the Granted Patent | 2022.06.29 |
| (86) | European Application Nr. | 16882156.9 |
| (86) | European Filing Date | 2016.12.30 |
| (87) | The European Application's Publication Date | 2018.11.07 |
| (30) | Priority | 2015.12.31, KR, 20150191082 2016.12.02, KR, 20160163737 |
| (84) | Designated Contracting States: | AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR |
| (73) | Proprietor | Hanmi Pharm. Co., Ltd., 214 Muha-ro Paltan-myeon, Hwaseong-si, Gyeonggi-do 18536, Sør-Korea |
| (72) | Inventor | OH, Euh Lim, 550 Dongtangiheung-ro, Hwaseong-si Gyeonggi-do 18469, Sør-Korea LEE, Jong Suk, 550 Dongtangiheung-ro, Hwaseong-si Gyeonggi-do 18469, Sør-Korea PARK, Young Jin, 550 Dongtangiheung-ro, Hwaseong-si Gyeonggi-do 18469, Sør-Korea LIM, Chang Ki, 550 Dongtangiheung-ro, Hwaseong-si Gyeonggi-do 18469, Sør-Korea JUNG, Sung Youb, 550 Dongtangiheung-ro, Hwaseong-si Gyeonggi-do 18469, Sør-Korea KWON, Se Chang, 550 Dongtangiheung-ro, Hwaseong-si Gyeonggi-do 18469, Sør-Korea |
| (74) | Agent or Attorney | Novagraaf Brevets, Bâtiment O2, 2 rue Sarah Bernhardt CS90017, 92665 ASNIÈRES-SUR-SEINE CEDEX, Frankrike |

| | | |
|------|-------------------|---|
| (54) | Title | TRIPLE ACTIVATOR ACTIVATING GLUCAGON, GLP-1 AND GIP RECEPTOR |
| (56) | References Cited: | US-A1- 2012 288 511, US-A1- 2013 203 659, KR-A- 20140 018 462, US-A1- 2013 116 173, US-A1- 2015 368 310, US-A1- 2012 329 715, WO-A2-2004/093823, US-A1- 2014 011 738, DRUCKER ET AL.: 'The Incretin System: Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes' THE LANCET vol. 368, no. 11, 2006, pages 1696 - 1705, XP027947354 |

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Isolert peptid som har funksjonen til en trippel agonist som kan aktivere glukagonreseptorer, glukagonlignende peptid-1-reseptorer (GLP-1-reseptorer) og
5 glukoseavhengige insulinotrope polypeptidreseptorer (GIP-reseptorer),
hvor det isolerte peptidet omfatter aminosyresekvensen valgt fra gruppen som består av SEQ ID NO: 21, 22, 42 og 96.
2. Farmasøytisk sammensetning omfattende peptidet ifølge krav 1.
10
3. Peptidet ifølge krav 1 for anvendelse i behandlingen av metabolsk syndrom, hvor det metabolske syndromet omfatter nedsatt glukosetoleranse, hyperkolesterolemi, dyslipidemi, fedme, diabetes, hypertensjon, arteriosklerose som følge av dyslipidemi, aterosklerose, arteriosklerose eller koronar hjertesykdom.